Rhumbline Advisers Reata Pharmaceuticals Inc Transaction History

Rhumbline Advisers

$109 Billion
Q3 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$79.22 - $105.37 $604,052 - $803,446	7,625 Added 18.87%	48,033 $4.9 Million
Q1 2023 May 11, 2023	BUY	$30.85 - $93.17 $44,917 - $135,655	1,456 Added 3.74%	40,408 $3.67 Million
Q4 2022 Feb 14, 2023	BUY	$22.15 - $42.11 $18,606 - $35,372	840 Added 2.2%	38,952 $1.48 Million
Q3 2022 Nov 10, 2022	BUY	$19.41 - $36.49 $63,412 - $119,212	3,267 Added 9.38%	38,112 $958,000
Q2 2022 Aug 11, 2022	BUY	$20.71 - $36.5 $100,733 - $177,536	4,864 Added 16.22%	34,845 $1.06 Million
Q1 2022 May 12, 2022	SELL	$24.12 - $39.6 $1,567 - $2,574	-65 Reduced 0.22%	29,981 $982,000
Q4 2021 Feb 10, 2022	SELL	$25.61 - $110.96 $10,013 - $43,385	-391 Reduced 1.28%	30,046 $792,000
Q3 2021 Nov 12, 2021	BUY	$100.0 - $143.02 $26,800 - $38,329	268 Added 0.89%	30,437 $3.06 Million
Q2 2021 Aug 05, 2021	BUY	$78.27 - $151.29 $374,052 - $723,014	4,779 Added 18.82%	30,169 $4.27 Million
Q1 2021 May 06, 2021	SELL	$94.25 - $132.81 $53,628 - $75,568	-569 Reduced 2.19%	25,390 $2.53 Million
Q4 2020 Feb 10, 2021	SELL	$102.03 - $184.62 $102 - $184	-1 Reduced -0.0%	25,959 $3.21 Million
Q3 2020 Nov 12, 2020	SELL	$93.53 - $163.34 $173,685 - $303,322	-1,857 Reduced 6.68%	25,960 $2.53 Million
Q2 2020 Aug 13, 2020	SELL	$126.3 - $176.56 $1.32 Million - $1.84 Million	-10,429 Reduced 27.27%	27,817 $4.34 Million
Q1 2020 May 06, 2020	BUY	$124.16 - $247.74 $389,117 - $776,417	3,134 Added 8.93%	38,246 $5.52 Million
Q4 2019 Feb 05, 2020	BUY	$74.57 - $217.92 $289,331 - $845,529	3,880 Added 12.42%	35,112 $7.18 Million
Q3 2019 Oct 23, 2019	BUY	$71.26 - $95.75 $123,208 - $165,551	1,729 Added 5.86%	31,232 $2.51 Million
Q2 2019 Aug 14, 2019	BUY	$77.72 - $94.35 $349,817 - $424,669	4,501 Added 18.0%	29,503 $2.78 Million
Q1 2019 May 01, 2019	BUY	$51.9 - $101.79 $363 - $712	7 Added 0.03%	25,002 $2.14 Million
Q4 2018 Jan 31, 2019	BUY	$48.76 - $76.44 $399,295 - $625,967	8,189 Added 48.73%	24,995 $1.4 Million
Q3 2018 Nov 07, 2018	BUY	$35.64 - $92.06 $51,000 - $131,737	1,431 Added 9.31%	16,806 $1.37 Million
Q2 2018 Aug 06, 2018	BUY	$19.94 - $40.96 $101,893 - $209,305	5,110 Added 49.78%	15,375 $538,000
Q1 2018 May 02, 2018	BUY	$20.0 - $30.19 $4,000 - $6,038	200 Added 1.99%	10,265 $211,000
Q4 2017 Feb 09, 2018	BUY	$22.39 - $33.27 $3,089 - $4,591	138 Added 1.39%	10,065 $285,000
Q3 2017 Nov 06, 2017	BUY	$26.29 - $31.88 $260,980 - $316,472	9,927	9,927 $309,000

Others Institutions Holding RETA

# of Institutions

Shares Held

62.7K

Call Options Held

Put Options Held

View Full List

About REATA PHARMACEUTICALS INC

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

More about RETA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account